AstraZeneca (AZN,AZN.L,ZEG.DE,AZN.ST) said BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. The approval was based on positive results from the BaxHTN Phase III trial.
BAXFENDY is a highly selective and potent aldosterone synthase inhibitor designed to lower blood pressure in a new way by specifically inhibiting the production of aldosterone, a hormone that raises blood pressure to unhealthy levels and increases the risk of heart and kidney problems.
AstraZeneca acquired BAXFENDY through its purchase of CinCor Pharma, in February 2023.
In pre-market trading on NYSE, AstraZeneca shares are up 0.20 percent to $182.04.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.